Drug evaluation: tesetaxel--an oral semisynthetic taxane derivative.
Daiichi Sankyo Co Ltd (formerly Daiichi Seiyaku Co Ltd) was developing the oral semisynthetic taxane derivative tesetaxel for the potential treatment of cancer, including colorectal and gastric cancer. However, despite early signs of promise, in November 2006 tesetaxel was removed from Daiichi's development pipeline for failure to show clear benefit over existing, currently marketed agents for cancer chemotherapy.
Roche
Maria
M
Massachusetts General Hospital, Division of Hematology and Oncology, 55 Fruit Street, Boston, MA 02114, USA.
Kyriakou
Helena
H
Seiden
Michael
M
D000818:Animals; D000972:Antineoplastic Agents, Phytogenic / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D017321:Clinical Trials, Phase I as Topic; D000075202:Contraindications; D004353:Drug Evaluation, Preclinical; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy*; D013329:Structure-Activity Relationship; D043823:Taxoids / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*
D000972:Antineoplastic Agents, Phytogenic; D043823:Taxoids; C479543:tesetaxel